Nanobiotix Stock
Nanobiotix Stock
Pros and Cons of Nanobiotix in the next few years
Pros
Cons
Performance of Nanobiotix vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Nanobiotix | 2.540% | 1.528% | 1.751% | 481.250% | 531.793% | 379.381% | 32.857% |
| Valneva SE | -2.240% | -2.740% | -4.031% | 102.367% | 76.454% | -43.463% | -45.636% |
| Transgene S.A. | 11.480% | 15.062% | -24.228% | 34.488% | 36.058% | -46.065% | -43.515% |
| Innate Pharma | 1.970% | 4.141% | 4.010% | 7.792% | -12.632% | -22.934% | -53.889% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon first glance, the financials of Nanobiotix, a company from the Biotechnology & Medical Research industry, seem to be facing a challenging financial situation. The company has continuously reported net losses and has a negative stockholder's equity as of the end of 2022. However, it is essential to dive deeper into the company's financial statements to better understand the underlying factors contributing to its current position.
Pros
Strong liquidity position: Nanobiotix's cash and short-term investments stood at €41,388,000 at the end of 2022, indicating a solid liquidity position to continue funding its research and development activities.
News
Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue
Nanobiotix (NASDAQ: NBTX) is a French biotechnology stock, and one that has soared 660% in 2025 as of Nov. 18. That's enough to draw investor attention, and to have many wondering if such torrid
